Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
A Phase I, Placebo-controlled, Double-blind, First-in-human Study to Investigate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-248 Solution in Healthy Subjects and Patients With Systemic Sclerosis (SSc)
Sponsor: CTC Clinical Trial Consultants AB
This PHASE1 trial investigates Healthy and is currently completed. CTC Clinical Trial Consultants AB leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Completed PHASE1
-
Oct 2021 — Oct 2023 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Aug 2019 — Oct 2020 [monthly]
Recruiting PHASE1
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CTC Clinical Trial Consultants AB
- Gesynta Pharma AB
For direct contact, visit the study record on ClinicalTrials.gov .